Source comparison
MK677 vs MK-677: Chemical Identity and Nomenclature Origins
MK677 same as MK-677 because both derive from the original Merck compound designation assigned during Phase I clinical trials in the 1990s. Merck & Co. developed ibutamoren as part of a broader secretagogue research program exploring non-peptide alternatives t
This comparison does not assign a generated winner or score.
- MK677 same as MK-677 because both derive from the original Merck compound designation assigned during Phase I clinical trials in the 1990s. Merck & Co. developed ibutamoren as part of a broader secretagogue research program exploring non-peptide alternatives to GHRP-6 and GHRP-2. Earlier peptide-based growth hormone releasers that required frequent injection and had limited oral bioavailability. The "MK" prefix indicated Merck as the originating institution, and 677 was the internal compound tracking number. Publications from that era used MK-677 with a hyphen as the standard research identifier.
- As the compound moved into open research and third-party synthesis, the hyphen was often dropped in informal contexts. Supplier catalogues, forum discussions, and non-peer-reviewed summaries frequently write it as MK677. Some databases index both forms separately, creating the false impression of two distinct molecules when cross-referencing studies. PubChem lists ibutamoren under CID 9939050 with MK-677 as the primary synonym and MK677 as a secondary variant. Confirming they reference the same chemical entity (2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide).
- The structural uniqueness of MK677 lies in its non-peptide backbone. Unlike GHRP analogues built from amino acid chains, ibutamoren is a spiro-indane derivative. A small-molecule mimic of ghrelin that binds the GHSR-1a receptor without undergoing proteolytic degradation in the gut. This allows oral administration with bioavailability exceeding 60%, a pharmacokinetic advantage peptide secretagogues cannot match. The half-life of approximately 24 hours means once-daily dosing maintains therapeutic plasma levels, contrasting sharply with hexarelin or GHRP-2, which require multiple daily injections to avoid trough periods.